Clinical Trial Update: Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 study compares the combination of ipilimumab and nivolumab versus ipilimumab alone in advanced melanoma, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma
• Melanoma of Unknown Primary
• Mucosal Melanoma
• Unresectable Melanoma

Drugs mentioned

• Opdivo (nivolumab) (nivolumab)
• Yervoy (Ipilimumab) (Ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Status: COMPLETED | Results posted: 2023-05-01